Studying Pathways of Resistance in KRAS-driven Cancers

计划入组 58 人 · 首次发布于 2022 年 3 月 9 日

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

计划入组 29 人 · 首次发布于 2026 年 4 月 21 日

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

计划入组 20 人 · 首次发布于 2025 年 6 月 4 日

MP-7046

KRAS inhibitors (CD3)

KRAS inhibitors (solid cancers)

KalVista Pharmaceuticals

United States

Exelixis, Inc.

United States

Cytokinetics, Incorporated

United States

KRAS Inhibitors Market Set for Growth with Novel Therapies Targeting Key Mutations in Cancer

Quanta Therapeutics' Direct KRAS Inhibitors Show Promise Against Resistance to Pan-RAS Tri-Complex Therapies

BlossomHill Therapeutics Unveils Next-Generation Pan-KRAS Inhibitors with Picomolar Potency at AACR 2026